Emerging evidence reveals a clinically significant rebound effect following the discontinuation of glucagon-like peptide-1 (GLP-1) agonists, characterised by weight regain, resurgence of cardiometabolic risk factors and relapse into maladaptive behaviours.
Yet there is no guarantee that patients living with obesity who gain access to GLP-1 medications during a clinical trial will remain engaged for the trial duration or be able to access the medications once the study ends.
This presents sponsors, sites, contract research organisations (CROs) and others in the clinical trial community with a unique opportunity to understand and proactively mitigate the effects of GLP-1 discontinuation.
Check out the rest of the feature here
